U.S.-based buyout and mezzanine fundraising picked right back up, piling $8.8 billion on top of its 2017 total. Thus far in 2017, private equity firms have raised $201.4 billion, leading this time a year ago by $24.6 billion, or 13.9 percent.
Athyrium Capital Management, focused on the global healthcare sector, wrapped up its third flagship. Athyrium Opportunities Fund III raised just over $2 billion in commitments.
Kohlberg Kravis Roberts more than doubled the target for its growth equity healthcare fund. KKR Health Care Strategic Growth Fund closed on $1.45 billion after originally aiming for $650 million.
New York’s Lightyear Capital beat its $950 million goal and closed its fourth primary fund at just over $1 billion. Also finalizing its fourth fund, Chicago-based Edgewater Funds closed Growth Capital Partners IV at $1 billion.
Dealmakers closed $6.2 billion in private equity-backed deals since Buyouts last went to press. The yearly aggregate now sits at $191.5 billion, ahead of 2016’s total by $38.9 billion, or 25.5 percent.
Of deals with disclosed value, a pair broke the billion-dollar threshold.
The larger of the two was for PharMerica Corp. KRR acquired the entire share capital of the drugstore operator for more than $1.3 billion.
Bain Capital followed by securing a majority interest in Asatsu-DK Inc. Bain’s 87 percent stake in the Tokyo-based advertising agency cost nearly $1.2 billion.
Additional Data
IPO REGISTRATIONS BY SELECT PRIVATE EQUITY-BACKED COMPANIES IN 2017 YTD
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: